Amelie D. G.
- Country
- Germany
- Department
- Department of Gynecology and obstetrics
Research Overview
- Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab versus Chemotherapy in Clinical Stage II-III Triple-Negative Early Breast Cancer
- A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy
- Randomized Study of Trastuzumab Deruxtecan Versus Standard of Care in HER2-Positive or HER2-Low Early Breast Cancer with Molecular Relapse
Data & Insights
Has run more than one trial at 69 of 213 partner sites.
Specializations
Breast Cancer and Gynecologic Oncology
Clinical research activity includes hormone receptor-positive breast cancer, HER2-negative breast cancer, and triple-negative breast cancer, with additional involvement in early breast cancer, locally advanced breast cancer, and metastatic breast cancer. The gynecologic focus extends to ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, and peritoneal cancer.
- Endocrine therapy
- CDK4/6 inhibition
- PARP inhibition
- Immunotherapy
Research interests also include adjuvant treatment, neoadjuvant treatment, and management of advanced solid tumours in women’s oncology.
Thoracic Malignancies
The investigator is active in studies of non-small cell lung cancer, small cell lung cancer, and unresectable stage III NSCLC, as well as metastatic lung cancer and PD-L1-selected disease. This area includes both first-line and later-line therapeutic strategies for lung cancer.
- Immune checkpoint blockade
- Targeted therapy
- Chemoradiotherapy
- Biomarker-selected treatment
Therapeutic interest also covers KRAS G12C-mutated NSCLC, EGFR-mutated NSCLC, and post-operative or post-chemoradiation lung cancer settings.
Gastrointestinal and Hepatopancreatobiliary Cancers
Research involvement spans gastric cancer, gastroesophageal junction adenocarcinoma, colorectal cancer, rectal cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer. The portfolio also includes broader work in advanced gastrointestinal tumors.
- Antibody-based therapy
- Combination chemotherapy
- Precision oncology
- Adjuvant treatment
Key therapeutic themes include biomarker-driven treatment, resectable disease, and management of metastatic gastrointestinal cancer.
Hematologic Malignancies
The investigator is engaged in clinical studies of acute myeloid leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndrome. Pediatric and adult blood cancers are represented across this research area.
- Antibody therapy
- Cell-cycle and pathway inhibition
- Intensive chemotherapy
- Maintenance treatment
Additional interest includes relapsed or refractory disease, high-risk leukemia, and transplant-related treatment strategies.
Urologic, Renal, and Other Solid Tumors
Clinical activity also covers muscle-invasive urothelial carcinoma, renal tumours, melanoma, cutaneous squamous cell carcinoma, endometrial cancer, and a range of advanced or metastatic solid tumors. This includes tumor-agnostic research and studies in biomarker-defined populations.
- Adjuvant immunotherapy
- Targeted treatment
- Precision medicine
- Metastatic disease control
Therapeutic interests extend to central nervous system involvement, leptomeningeal disease, and other difficult-to-treat advanced malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.